Gopal Chalavarya, MD
Cardiovascular Disease · Hudson, FLNPI 1922093921
Payments from drug & device makers
What this record shows
This record is dominated by other: $33,833 of the $40,011 with a category attached, or 84.6%. Angiodynamics, Inc. accounts for 84.6% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $12,124, 3.7 times the $3,252 reported in 2019. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $400.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$34K
- Penumbra, Inc.$1K
- Boston Scientific$1K
- Medtronic$812
- Abbott$472
- Johnson & Johnson$468
- plus $2K from 21 others
Across 4 payments — averaging $1116.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$4K
What the payments were for
- Travel & lodging$1,4854%
- Food & beverage$4,69212%
- Other$33,83385%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 4 | $33,833 |
| Penumbra, Inc. | 4 | $1,269 |
| Boston Scientific | 8 | $1,040 |
| Medtronic(2 entities) | 22 | $812 |
| Abbott | 6 | $472 |
| Johnson & Johnson | 8 | $468 |
| Endologix LLC | 2 | $348 |
| Janssen Scientific Affairs, LLC | 2 | $210 |
| Recor Medical Inc | 2 | $194 |
| Edwards Lifesciences | 1 | $183 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $162 |
| AstraZeneca | 3 | $158 |
| Abiomed | 2 | $157 |
| Boehringer Ingelheim | 5 | $119 |
| Novartis | 5 | $97 |
| EKOS Corporation | 1 | $97 |
| Cardiovascular Systems Inc. | 6 | $80 |
| Shockwave Medical, Inc | 1 | $66 |
| Pfizer | 2 | $51 |
| Cook Medical LLC | 3 | $45 |
| Kestra Medical Technology Services, Inc. | 1 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Insulet Corporation | 1 | $23 |
| Philips North America LLC | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Catheter Precision, Inc. FKA Ra Medical Systems, Inc. | 2 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$33,833
- Indigo$1,043
- ANGIOJET$887
- XARELTO$352
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$183
- PARADISE RENAL DENERVATION SYSTEM$177
- MitraClip System$175
- Mitra Clip system$150
- Indigo System$131
- LINQ II$125
- FARXIGA$124
- LifeVest$112
- INVOKANA$111
How this compares
$40,011 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 212 | $223,288 |
| EntrestoSacubitril/Valsartan | 68 | $74,895 |
| XareltoRivaroxaban | 55 | $56,985 |
| MultaqDronedarone Hcl | 16 | $16,889 |
| BrilintaTicagrelor | 22 | $15,090 |
| JardianceEmpagliflozin | 15 | $14,801 |
| FarxigaDapagliflozin Propanediol | 15 | $11,359 |
| Nitroglycerin PatchNitroglycerin | 74 | $4,342 |
| Verapamil ErVerapamil Hcl | 52 | $3,972 |
| Verapamil SrVerapamil Hcl | 60 | $3,490 |
| Nitroglycerin | 100 | $2,422 |
| Metoprolol Succinate | 207 | $2,098 |
| Amiodarone Hcl | 64 | $2,059 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 115 | $2,050 |
| Atorvastatin Calcium | 120 | $1,981 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $51 | $223,288212 claims |
| NovartisEntresto | $97 | $74,89568 claims |
| Johnson & JohnsonXarelto | $468 | $56,98555 claims |
| AstraZenecaBrilinta, Farxiga | $158 | $26,44937 claims |
| Sanofi-aventis U.S. LLCMultaq | $30 | $16,88916 claims |
| Boehringer IngelheimJardiance | $119 | $14,80115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Hudson
- Keshavulueddy RamireddyHudson$105K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.